社长人妻与黑人中出视频-欧洲成人一区二区精视频-插小骚B 啊啊啊疼视频-不卡高清一区二区三区

普洛藥業(yè)
DS Technology Platforms
Flow Chemistry Synthetic Biology & Biocatalysis Crystallization & Particle Engineering Peptide High Potency Compound Conjugate Library Service Oligonucleotide Synthesis Preparation & Purification
Conjugate Library Service Platform
Apeloa Conjugate Library Service Platform offers comprehensive services for the development of targeted protein degradation therapeutics, including PROteolysis Trgeting Chimeras (PROTACs). With over 80 PROTAC-focused scientists and two dynamic chemistry service teams located in Boston and Hengdian, the platform provides expertise throughout the entire PROTAC development process. From target validation, hit generation, lead optimization, to clinical development, Apeloa leverages its integrated parallel synthesis platform, extensive E3 ligand, linker, and POI binder intermediate libraries, and strong analytical and ADME capabilities to drive PROTAC projects forward efficiently.
普洛藥業(yè)
Team
Apeloa Conjugate Library Service Platform is led by a team of highly experienced scientists, including co-inventors of two approved NDAs and one Phase II IND. The team comprises 12 Ph.D. holders with a combined synthetic chemistry experience of over 100 years, and a tot
Services
● Design, synthesis, and optimization of PROTAC molecules ● Synthesis and optimization of E3 ligands, linkers, and POI binders ● Rapid construction of early screening intermediate libraries via parallel synthesis platform ● Analytical, purification, and ADME evaluation studies ● Non-GMP and GMP scale-up production services
Equipment
●400Hz/600Hz NMR (Bruker/Avance) ●LC-Q-TOF (Agilent) ●LC-MSMS (Shimadzu/Waters/Agilent) ●GC-MSMS (Agilent/Shimadzu) ●HPLC (Waters) ●XRD (Rigaku) ●ICP-MS (Perkin Elmer)
Advantages 1
Advantages 2
Advantages 3
Advantages 4
Advantages 5
普洛藥業(yè)
Extensive Intermediate Library
● Over 300 E3 ligands and ligand-linker conjugates in stock ● Expedites PROTAC synthesis and screening
普洛藥業(yè)
Flexible E3 Ligand and Linker Combinations
● Facilitates optimization of degradation efficiency and physiochemical properties
普洛藥業(yè)
Efficient Parallel Synthesis Platform
Rapid construction of intermediate libraries for early screening
普洛藥業(yè)
Expertise in E3 Ligand Scale-up
● Optimized synthetic routes for key clinical PROTAC ligands (e.g., Kymera CRBN, ARV-471, ARV-110) ● Improved yields, reduced costs, and addressed challenges like epimerization
普洛藥業(yè)
Retrosynthetic Approach for PROTAC Synthesis
● Avoids epimerization and purification challenges ● Utilizes easy-to-purify fragments and conjugate intermediates